Background Novel treatment options are needed for pediatric patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Upadacitinib (UPA) is an oral, selective Janus kinase (JAK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results